|1.||Yoshihara, Shigemi: 4 articles (06/2014 - 10/2007)|
|2.||Arisaka, Osamu: 4 articles (06/2014 - 10/2007)|
|3.||Fukuda, Hironobu: 3 articles (06/2014 - 08/2009)|
|4.||Yamada, Yumi: 3 articles (06/2014 - 10/2007)|
|5.||Yoshimura, Naoki: 3 articles (10/2007 - 05/2002)|
|6.||Liu, Dan: 2 articles (07/2014 - 07/2013)|
|7.||Li, Yun: 2 articles (07/2014 - 07/2013)|
|8.||Ono, Mika: 2 articles (06/2014 - 08/2009)|
|9.||Hashizume, Hideo: 2 articles (03/2014 - 09/2005)|
|10.||Fujimura, Masaki: 2 articles (01/2008 - 01/2004)|
|1.||Asthma (Bronchial Asthma)
01/01/2014 - "Treatment with suplatast tosilate was effective in improving all histopathological parameters in a mouse model of chronic asthma. "
06/01/2011 - "Suplatast tosilate is a Th2 cytokine inhibitor that is effective for controlling persistent asthma. "
01/01/2003 - "Treatment with suplatast tosilate improved pulmonary function in patients with bronchial asthma. "
09/01/2005 - "In the present study, we attempted to clarify the effect of suplatast tosilate on DC1/DC2 balance in asthma. "
07/22/2000 - "Our aim was to study the effect of suplatast tosilate, a selective Th2 cytokine inhibitor, on asthma control and asthma exacerbations during reduction of inhaled corticosteroid dose in patients with steroid-dependent asthma. "
07/01/2013 - "Suplatast tosilate ameliorates airway hyperreactivity and inflammation through inhibition of the GATA‑3/IL‑5 signaling pathway in asthmatic rats."
01/01/2010 - "Suplatast tosilate might suppress this inflammation by inhibiting eotaxin production."
03/01/2007 - "Intravesical suplatast tosilate (IPD-1151T) inhibits experimental bladder inflammation."
09/01/2005 - "Suplatast tosilate is an antiallergic drug that selectively suppresses Th2-cytokine production and inhibits airway hyperresponsiveness and eosinophilic airway inflammation. "
09/01/2004 - "Through inhibition of chemotaxis, IPD-1151T might limit the number of eosinophils at the inflammation site. "
|3.||Atopic Dermatitis (Atopic Eczema)
11/01/2003 - "From the above mentioned results, we confirmed the high efficacy of suplatast tosilate in the treatment of atopic dermatitis."
03/01/1999 - "This study was designed to elucidate the mechanisms of the rebound phenomenon, and to test the effect of an oral anti-allergic medication, suplatast tosilate, on atopic dermatitis. "
11/01/2003 - "The Th2 cytokine inhibitor, suplatast tosilate (300 mg/day) was administered to 45 cases of patients with atopic dermatitis for 8 weeks. "
11/01/2003 - "[The effect of suplatast tosilate on the patients with atopic dermatitis--relationship between clinical symptoms and immunological parameters]."
12/01/2000 - "From the above mentioned results, the high efficacy and safety of suplatast tosilate in the treatment of severe atopic dermatitis were confirmed. "
01/01/2009 - "Suplatast tosilate may be useful for the treatment of allergic rhinitis by attenuating the inflammation of the effector phase."
01/01/2009 - "To elucidate the functions of Th2 cytokines in allergic rhinitis, we examined the in vivo effects of the Th2 cytokine inhibitor suplatast tosilate on mucus hypersecretion and eosinophil infiltration in rat nasal epithelium. "
11/01/2002 - "Suplatast tosilate (IPD-1151T), a selective Th2 cytokine inhibitor that suppresses the production of interleukin (IL)-4 and IL-5 in vitro or in animal models has been proved clinically effective for allergic rhinitis (AR). "
01/01/2004 - "After making the diagnosis of CVA, an inhaled corticosteroid or a Th2 cytokine production inhibitor suplatast tosilate was administered to patients; consequently, they showed no recurrence of cough. "
01/01/2008 - "Oral administration of suplatast tosilate may be a novel therapy for atopic cough."
06/01/2002 - "Twenty patients with cough-variant asthma (CVA) were assigned to a suplatast tosilate (100 mg three times daily) group or a placebo group for 6 weeks in a double-blind randomized study. "
06/01/2002 - "Our study objective was to determine the effect of suplatast tosilate, a Th2 cytokine inhibitor, on patients with cough-variant asthma. "
09/01/2009 - "We assessed the clinical usefulness of suplatast tosilate (IPD) for chronic dry cough after lung cancer surgery. "
|1.||Interleukin-5 (Interleukin 5)
|3.||Immunoglobulin E (IgE)
|5.||Interleukin-4 (Interleukin 4)
|10.||Eosinophil Cationic Protein